Agilon Health (AGL) EBITDA Margin (2020 - 2026)

Agilon Health (AGL) has 7 years of EBITDA Margin data on file, last reported at 0.28% in Q1 2026.

• Quarterly EBITDA Margin rose 172.0% year-over-year to 0.28% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7.51% (down 238.0% YoY) and the FY2025 annual result came in at 7.81%, down 299.0% from the prior year.
• EBITDA Margin rose to 0.28% in Q1 2026, from 12.35% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 0.28% in Q1 2026 to a low of 15.56% in Q4 2023.
• A 5-year average of 5.56% and a median of 3.46% in 2023 frame the typical range for EBITDA Margin.
• Annual changes were most pronounced in 2022 — EBITDA Margin surged 5666 bps — and 2024, when it sank 575 bps.
• Tracing AGL's EBITDA Margin over 5 years: stood at 14.62% in 2022, then decreased by 6 bps to 15.56% in 2023, then jumped by 54 bps to 7.1% in 2024, then plunged by 74 bps to 12.35% in 2025, then soared by 102 bps to 0.28% in 2026.
• The last three EBITDA Margin figures came in at 0.28% (Q1 2026), 12.35% (Q4 2025), and 9.15% (Q3 2025), per Business Quant data.